Menopause is one of the fastest-growing reasons people search for creatine. The pitch usually bundles three claims: that creatine protects muscle, that it protects bone, and that it eases menopausal symptoms such as brain fog, low mood and hot flashes. The trials test those claims very unevenly. Muscle and bone have seven randomised trials and a meta-analysis. Symptoms have one small trial. Hot flashes have nothing.
The postmenopausal muscle and bone trials are set out in full, with their tables, on creatine for older adults, and the sex imbalance in the creatine literature is on creatine for women. This page is about what those trials mean for menopause specifically, and about the symptom questions they do not answer.
Muscle and strength: small, and only with training
The best summary is a 2026 meta-analysis in the Journal of the International Society of Sports Nutrition: seven randomised placebo-controlled trials, 608 postmenopausal women, mean age about 62, lasting 12 to 104 weeks.
- Lean mass: +0.37 kg with creatine (95% CI +0.05 to +0.69), from five trials. The 95% prediction interval runs from −0.10 to +0.84 kg, so a new trial could plausibly find nothing.
- Leg-press strength: +7.5 kg on the one-repetition maximum (95% CI +2.2 to +12.8), from three trials, with no heterogeneity.
- The split that matters: benefits appeared where creatine at 5 g a day or more was combined with resistance training. Trials using 3 g a day or less without training showed no measurable effect.
That split is the single most useful finding for this question. The two trials without training — 1 g a day for a year in 109 women and 3 g a day for two years in 200 women, both from São Paulo — found no change in lean mass or muscle function. The menopause benefit, such as it is, belongs to creatine plus lifting, not to creatine alone.
Three disclosures sit with the meta-analysis: one author chairs a creatine advisory board supported by the creatine maker Alzchem, another heads a society that receives funding from creatine sellers, and Alzchem paid part of the publication fee. The review was not prospectively registered.
Bone: the long trials found no difference in density
Menopause accelerates bone loss, and creatine has been tested against it for up to two years:
| Trial | Women | Creatine | Bone density result |
|---|---|---|---|
| Chilibeck et al. 2015 | 47 randomised, 33 analysed, mean age 57, resistance training | 0.1 g/kg a day, 12 months | Femoral-neck loss −1.2% vs −3.9% on placebo; no difference at the spine |
| Sales et al. 2020 | 200 with osteopenia, no training | 3 g a day, 2 years | No difference at any site |
| Chilibeck et al. 2023 | 237, mean age 59, resistance training and walking | 0.14 g/kg a day, 2 years | No difference at femoral neck, hip or spine; two femoral-neck geometry measures preserved |
The figures are as each trial reports them; none of them is a recommendation.
The early positive result came from a small trial with heavy dropout. The two largest trials, with 437 women between them, found no effect on density. The 237-woman trial did find that creatine preserved bone-geometry measures linked to bending strength, and shortened an 80 m walk by about 1.5 seconds — but fracture risk itself has never been measured. The detailed figures are on creatine for older adults.
One detail for anyone checking the record: the 2015 one-year trial at 1 g a day and the 2020 two-year trial at 3 g a day both cite the same ClinicalTrials.gov registration number, NCT01472393.
Symptoms: one small trial
The only randomised trial built around menopause symptoms is CONCRET-MENOPA, published in 2025–26 by Sergej Ostojic's group in Novi Sad. Thirty-six healthy perimenopausal and menopausal women, mean age 50, were randomised to one of four arms for eight weeks:
| Arm | Daily amount | Result vs placebo |
|---|---|---|
| Creatine HCl, low | 750 mg | No advantage reported in the abstract |
| Creatine HCl, medium | 1,500 mg | Reaction time improved (6.6% vs 1.2%); frontal brain creatine up 16.4% vs 0.9%; blood lipids improved; mood-swing severity lower but not significant (p = 0.06) |
| Creatine HCl + creatine ethyl ester | 800 mg | No advantage reported in the abstract |
| Placebo | — | — |
The figures are as the trial reports them; none of them is a recommendation.
Three things limit this. With nine women per arm, the trial could detect only large effects. It used creatine hydrochloride at a fraction of the gram doses in the muscle trials, so it says nothing about monohydrate at 3–5 g. And it did not measure hot flashes or night sweats. The lead author discloses advisory work for a creatine manufacturer, patents on creatine products and a company developing creatine-enriched foods. A companion scan study from the same authors found lower whole-brain creatine in 12 perimenopausal women than in younger adults, with lower regional levels tracking more concentration difficulties — a reason to test the idea properly, not a test of it.
The HCl form and its claims are on creatine HCl; mood and memory claims across all populations are on creatine and the brain claims.
Hot flashes, sleep and weight: not tested
A PubMed search on 2026-10-22 for creatine with hot flash, hot flush, night sweats or vasomotor terms returned 19 records. Most are case reports and cardiology papers where "creatine" means the enzyme creatine kinase. The only creatine supplementation trial among them is CONCRET-MENOPA, which mentions hot flashes only in its definition of perimenopause — none of the 19 measured a vasomotor symptom as an outcome. Menopausal sleep disturbance has not been a creatine trial outcome either: the sleep studies collected on creatine and sleep measured sleep in small groups or cognition under deprivation, and none enrolled women defined as menopausal. Midlife weight gain has not been tested either; the scale effect of creatine in the first weeks is water, set out on the early weight-gain page.
What is in the registry
A ClinicalTrials.gov search on 2026-10-22 for creatine with the term menopause returned five records. One is an unrelated heart-rhythm trial. The others:
- NCT06660004 — CONCRET-MENOPA, completed and published (above).
- NCT07027800 — high-intensity resistance training plus creatine in perimenopause, completed, with no results posted.
- NCT07729930 — creatine and middle-aged women (cognition, strength, fatigue, blood pressure), recruiting.
- NCT07580846 — the ATENEA study of adherence to creatine supplementation in estrogen-depleted women, recruiting.
So the perimenopause evidence is about to grow, and none of the registered trials lists hot flashes among its conditions.
What is not established
- Any effect on hot flashes, night sweats or other vasomotor symptoms. Never measured.
- Any effect on fracture risk. Bone density did not change in the largest trials; fractures were not an outcome.
- Whether symptom effects hold at ordinary monohydrate amounts, or in a trial larger than 36 women.
- Whether creatine alone, without resistance training, does anything measurable for muscle after menopause. The trials without training found nothing.
Menopause care — including hormone therapy, bone-density screening and any supplement decision — belongs with a clinician who knows the person's history.
Sources
All opened 2026-10-22.
- Naddafha S, Antonio J, Kreider RB, Stout JR. "Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis." J Int Soc Sports Nutr 2026;23(1):2668435. PMID 42141930
- Korovljev D et al. "The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA)." J Am Nutr Assoc 2026;45(3):199–210. PMID 40854087
- Ostojic SM, Ostojic J. "Brain creatine, estradiol and neurocognitive complaints in perimenopausal women: an exploratory cross-sectional study." Neurosci Lett 2026;880:138616. PMID 42061673
- Chilibeck PD et al. "Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women." Med Sci Sports Exerc 2015;47(8):1587–95. PMID 25386713
- Sales LP et al. "Creatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial." J Gerontol A 2020;75(5):931–938. PMID 31257405
- Lobo DM et al. "Effects of long-term low-dose dietary creatine supplementation in older women." Exp Gerontol 2015;70:97–104. PMID 26192975
- Chilibeck PD et al. "A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health." Med Sci Sports Exerc 2023;55(10):1750–1760. PMID 37144634
- PubMed census: creatine AND (hot flash/flashes, hot flush/flushes, night sweats, vasomotor) in title/abstract, 19 records, run 2026-10-22.
- ClinicalTrials.gov API v2: intervention "creatine", term "menopause", 5 records, queried 2026-10-22.